A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1

HIV Medicine

Volumn 9, Issue 3, 2008, Pages 160-171

  Garcia Perez, J ^a   Perez Olmeda, M ^a   Sanchez Palomino, S ^a,c   Perez Romero, P ^b   Alcami, J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Drug resistance; Protease; Renilla luciferase; Replicative fitness; Reverse transcriptase

Indexed keywords

LUCIFERASE; POL PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE, VIRAL; GENES, REPORTER; GENETIC VECTORS; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LUCIFERASES, RENILLA; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 39549101761     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00540.x     Document Type: Article

References (52)

1. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362:22-29.
2. Smith CJ, Sabin CA, Youle MS et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190:1860-1868.
3. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
4. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV cohort study. Lancet 1999; 353:863-868.
5. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181:946-953.
6. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
7. Barbour JD, Wrin T, Grant RM et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76:11104-11112.
8. Sufka SA, Ferrari G, Gryszowka VE et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: Immune response and viral control. J Infect Dis 2003; 187:1027-1037.
9. Kaplan SS, Ferrari G, Wrin T et al. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. AIDS Res Hum Retroviruses 2005; 21:13-16.
10. Stoddart CA, Liegler TJ, Mammano F et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001; 7:712-718.
11. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock. Nat Immunol 2000; 1:285-289.
12. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332:201-208.
13. Rosenberg ES, Billingsley JM, Caliendo AM et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
14. Descamps D, Flandre P, Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA 2000; 283:205-211.
15. Quinones-Mateu ME, Arts EJ. Fitness of drug resistant HIV-1: Methodology and clinical implications. Drug Resist Updat 2002; 5:224-233.
16. Nijhuis M, Deeks S, Boucher C. Implications of antiretroviral resistance on viral fitness. Current Opinion in Infectious Diseases 2001; 14:23-28.
17. Back NK, Nijhuis M, Keulen W et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15:4040-4049.
18. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-3752.
19. Prado JG, Wrin T, Beauchaine J et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002; 16:1009-1017.
20. de la Carriere LC, Paulous S, Clavel F, Mammano F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J Virol 1999; 73:3455-3459.
21. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998; 72:3300-3306.
22. Wrin T, Gamarnik AV, Whitehurst N et al. Natural variation of replication capacity measurements in drug-naïve/susceptible HIV-1. Antiviral Therapy 2001; 6(Suppl. 1):20.
23. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998; 72:3773-3778.
24. Martinez-Picado J, Savara AV, Shi L, Sutton L, D'Aquila RT. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000; 275:318-322.
25. Yuste E, Sanchez-Palomino S, Casado C, Domingo E, Lopez-Galindez C. Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol 1999; 73:2745-2751.
26. Quinones-Mateu ME, Ball SC, Marozsan AJ et al. A dual infection/ competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000; 74:9222-9233.
27. Lu J, Kuritzkes DR. A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J Acquir Immune Defic Syndr 2001; 27:7-13.
28. Weber J, Rangel HR, Chakraborty B et al. A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J Gen Virol 2003; 84:2217-2228.
29. Zhang H, Zhou Y, Alcock C et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004; 78:1718-1729.
30. Neumann T, Hagmann I, Lohrengel S et al. T20-insensitive HIV-1 from naïve patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology 2005; 333:251-262.
31. Weber J, Weberova J, Carobene M et al. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 2006; 136:102-117.
32. Robinson LH, Myers RE, Snowden BW, Tisdale M, Blair ED. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays. AIDS Res Hum Retroviruses 2000; 16:1149-1156.
33. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 2001; 75:3291-3300.
34. Deeks SG, Grant RM, Wrin T et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 2003; 17:361-370.
35. Barbour JD, Hecht FM, Wrin T et al. Higher CD+ T cell counts associated with low viral pol replication capacity among treatment-naïve adults in early HIV-1 infection. J Infect Dis 2004; 190:251-256.
36. Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, Fernandez B, Alcami J. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol 2007; 79:127-137.
37. Adachi A, Gendelman HE, Koenig S et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59:284-291.
38. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90:8392-8396.
39. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985; 229:563-566.
40. Fisher AG, Ratner L, Mitsuya H et al. Infectious mutants of HTLV-III with changes in the 3′ region and markedly reduced cytopathic effects. Science 1986; 233:655-659.
41. Terwilliger E, Sodroski JG, Rosen CA, Haseltine WA. Effects of mutations within the 3′ orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity. J Virol 1986; 60:754-760.
42. Muller B, Daecke J, Fackler OT, Dittmar MT, Zentgraf H, Krausslich HG. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 2004; 78:10803-10813.
43. Brown A, Gartner S, Kawano T, Benoit N, Cheng-Mayer C. HLA-A2 down-regulation on primary human macrophages infected with an M-tropic EGFP-tagged HIV-1 reporter virus. J Leukoc Biol 2005; 78:675-685.
44. van Maarseveen NM, Huigen MC, de Jong D, Smits AM, Boucher CA, Nijhuis M. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods 2006; 133:185-194.
45. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-3446.
46. Deval J, White KL, Miller MD et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279:509-516.
47. Gallant JE, Gerondelis PZ, Wainberg MA et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: A clinical review of antiretroviral resistance. Antivir Ther 2003; 8:489-506.
48. Menendez-Arias L, Este JA. HIV-resistance to viral entry inhibitors. Curr Pharm Des 2004; 10:1845-1860.
49. Quinones-Mateu ME, Arts EJ. Virus fitness: Concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol 2006; 299:83-140.
50. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78:4628-4637.
51. Menzo S, Castagna A, Monachetti A et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48:3253-3259.
52. Haubrich R, Wrin T, Hellmann N et al. Replication capacity as a predictor of immunological and virological benefit despite virological failure of an antiretroviral regimen. Antivir Ther 2002; 7:S101.